SC
MRVI icon

Schubert & Co’s Maravai LifeSciences MRVI Stock Holding History

Schubert & Co’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10
Closed -$141 – 948
2023
Q1 		$141 Buy
10
+1
+11% +$14 ﹤0.01% 1578
2022
Q4 		$129 Buy
9
+8
+800% +$126 ﹤0.01% 1558
2022
Q3 		$0 Buy
+1
New +$25 ﹤0.01% 1497

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Schubert & Co's MRVI Position: Q2 2023 in Review

Schubert & Co sold out of Maravai LifeSciences (MRVI) in Q2 2023, closing a stake of 10 shares — an estimated $141 sold.

Schubert & Co first reported a position in MRVI in Q3 2022 and held it in 3 quarters. The position peaked at $141 in Q1 2023. 221 funds tracked by Wall St. Rank hold MRVI as of Q2 2023.

  • Schubert & Co reported no remaining Maravai LifeSciences position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 10 Maravai LifeSciences shares in Q2 2023, an estimated $141.
  • Schubert & Co first reported a position in Maravai LifeSciences in Q3 2022 and held it in 3 quarters.
  • Schubert & Co's Maravai LifeSciences position peaked at $141 in Q1 2023.
  • 221 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.